Development	development	O	O	O	O
of	of	O	O	O	O
ocular	ocular	O	O	OTHERS	I
myasthenia	myasthenia	O	O	OTHERS	I
during	during	O	O	O	O
pegylated	pegylated	O	O	OTHERS	I
interferon	interferon	O	O	OTHERS	I
and	and	O	O	O	O
ribavirin	ribavirin	CHEMICALS	O	OTHERS	I
treatment	treatment	O	O	O	O
for	for	O	O	O	O
chronic	chronic	O	O	O	O
hepatitis	hepatitis	O	DISEASE	OTHERS	I
C.A	c.a	O	O	O	O
63-year-old	63-year-old	O	O	O	O
male	male	O	O	O	O
experienced	experienced	O	O	O	O
sudden	sudden	O	O	O	O
diplopia	diplopia	O	O	OTHERS	I
after	after	O	O	O	O
9	9	O	O	O	O
weeks	weeks	O	O	O	O
of	of	O	O	O	O
administration	administration	O	O	O	O
of	of	O	O	O	O
pegylated	pegylated	O	O	OTHERS	I
interferon	interferon	O	O	OTHERS	I
(	(	O	O	OTHERS	I
IFN	ifn	O	O	OTHERS	I
)	)	O	O	OTHERS	I
alpha-2b	alpha-2b	O	O	OTHERS	I
and	and	O	O	O	O
ribavirin	ribavirin	CHEMICALS	O	OTHERS	I
for	for	O	O	O	O
chronic	chronic	O	DISEASE	OTHERS	I
hepatitis	hepatitis	O	DISEASE	OTHERS	I
C	c	O	DISEASE	OTHERS	I
(	(	O	O	O	O
CHC	chc	O	O	OTHERS	I
)	)	O	O	O	O
.	.	O	O	O	O

Ophthalmologic	ophthalmologic	O	O	O	O
examinations	examinations	O	O	O	O
showed	showed	O	O	O	O
ptosis	ptosis	O	O	OTHERS	I
on	on	O	O	OTHERS	I
the	the	O	O	OTHERS	I
right	right	O	O	OTHERS	I
upper	upper	O	O	OTHERS	I
lid	lid	O	DISEASE	OTHERS	I
and	and	O	O	O	O
restricted	restricted	O	O	OTHERS	I
right	right	O	O	OTHERS	I
eye	eye	O	O	OTHERS	I
movement	movement	O	O	OTHERS	I
without	without	O	O	O	O
any	any	O	O	O	O
other	other	O	O	O	O
neurological	neurological	O	O	O	O
signs	signs	O	O	O	O
.	.	O	O	O	O

A	a	O	O	O	O
brain	brain	O	O	O	O
imaging	imaging	O	O	O	O
study	study	O	O	O	O
and	and	O	O	O	O
repetitive	repetitive	O	O	O	O
nerve	nerve	O	O	O	O
stimulation	stimulation	O	O	O	O
test	test	O	O	O	O
indicated	indicated	O	O	O	O
no	no	O	O	O	O
abnormality	abnormality	O	O	O	O
.	.	O	O	O	O

The	the	O	O	O	O
acetylcholine	acetylcholine	CHEMICALS	O	OTHERS	I
receptor	receptor	O	O	O	O
antibody	antibody	O	O	O	O
titer	titer	O	O	O	O
and	and	O	O	O	O
response	response	O	O	O	O
to	to	O	O	O	O
acetylcholinesterase	acetylcholinesterase	CHEMICALS	O	OTHERS	I
inhibitors	inhibitors	CHEMICALS	O	OTHERS	I
were	were	O	O	O	O
negative	negative	O	O	O	O
,	,	O	O	O	O
and	and	O	O	O	O
the	the	O	O	O	O
results	results	O	O	O	O
of	of	O	O	O	O
thyroid	thyroid	O	O	O	O
function	function	O	O	O	O
tests	tests	O	O	O	O
were	were	O	O	O	O
normal	normal	O	O	O	O
.	.	O	O	O	O

The	the	O	O	O	O
patient	patient	O	O	O	O
's	's	O	O	O	O
ophthalmological	ophthalmological	O	O	O	O
symptoms	symptoms	O	O	O	O
improved	improved	O	O	O	O
rapidly	rapidly	O	O	O	O
3	3	O	O	O	O
weeks	weeks	O	O	O	O
after	after	O	O	O	O
discontinuation	discontinuation	O	O	O	O
of	of	O	O	O	O
pegylated	pegylated	O	O	OTHERS	I
IFN	ifn	O	O	OTHERS	I
alpha-2b	alpha-2b	O	O	OTHERS	I
and	and	O	O	O	O
ribavirin	ribavirin	CHEMICALS	O	OTHERS	I
.	.	O	O	O	O

The	the	O	O	O	O
ocular	ocular	O	O	OTHERS	I
myasthenia	myasthenia	O	O	OTHERS	I
associated	associated	O	O	O	O
with	with	O	O	O	O
combination	combination	O	O	O	O
therapy	therapy	O	O	O	O
of	of	O	O	O	O
pegylated	pegylated	O	O	OTHERS	I
IFN	ifn	O	O	OTHERS	I
alpha-2b	alpha-2b	O	O	OTHERS	I
and	and	O	O	O	O
ribavirin	ribavirin	CHEMICALS	O	OTHERS	I
for	for	O	O	O	O
CHC	chc	O	O	OTHERS	I
is	is	O	O	O	O
very	very	O	O	O	O
rarely	rarely	O	O	O	O
reported	reported	O	O	O	O
;	;	O	O	O	O
therefore	therefore	O	O	O	O
,	,	O	O	O	O
we	we	O	O	O	O
present	present	O	O	O	O
this	this	O	O	O	O
case	case	O	O	O	O
with	with	O	O	O	O
a	a	O	O	O	O
review	review	O	O	O	O
of	of	O	O	O	O
the	the	O	O	O	O
various	various	O	O	O	O
eye	eye	O	O	O	O
complications	complications	O	O	O	O
of	of	O	O	O	O
IFN	ifn	O	O	OTHERS	I
therapy	therapy	O	O	O	O
.	.	O	O	O	O

